11 – 20 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians
(
- Contribution to journal › Article
-
Mark
Quantification of amyloid PET for future clinical use : a state-of-the-art review
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article